Reuters
18 Jun 2026, 10:45 UTC · 2h ago
Merck's pneumococcal vaccine wins US approval for high-risk children, teens
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
Reuters
18 Jun 2026, 10:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
What the story claims
1 claim · each scored for market impact
The U.S. health regulator approved an expanded use of Merck's pneumococcal vaccine for high-risk children and teenagers with chronic conditions. — Expanding the target patient population typically increases potential revenue and market share for the specific drug.
+0.40Which stocks this story touches
The FDA approved an expanded use of the company's pneumococcal vaccine, increasing its potential market.
Continue reading
6 related stories
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
42m ago
